// App-Quantinova.ai

4738 : The BET family bromodomain inhibitor ABBV-075 is a promising therapeutic agent for acute myeloid leukemia and myelodysplastic syndrome

Researchers

Presenter

  • Mai H. Bui

Principal Investigators

  • Xiaoyu Lin

  • Xiaoli Huang

  • Leiming Li

  • Aparna Sarthy

  • Daniel Albert

  • Terry Magoc

  • Lloyd Lam

  • Paul Hessler

  • Tamar Uziel

  • Steven Elmore

  • Keith McDaniel

  • Warren Kati

  • Yu Shen

Medical Centers

  • AbbVie, Inc., North Chicago, IL

Locations

  • United States

Companies

  • AbbVie Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Alpha-thalassemia myelodysplasia syndrome

  • Acute myelocytic leukemia

  • Solid malignancies

Biomarkers

  • B-cell lymphoma 2

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Vidaza

  • Venetoclax

  • abbv-075

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved